Optinose Stockholders Approve Merger with Paratek

Optinose ( (OPTN) ) just unveiled an update.

On May 16, 2025, OptiNose, Inc. held a special meeting of stockholders where key proposals were voted on. The company, involved in a merger with Paratek Pharmaceuticals, Inc., had 10,127,381 shares eligible to vote, with a quorum of 8,406,605 shares represented. The stockholders approved the Merger Agreement Proposal with Paratek, receiving a 77.96% affirmative vote. Additionally, the Advisory Compensation Proposal was approved with an 81.65% affirmative vote. The Adjournment Proposal was deemed unnecessary due to sufficient votes for the merger.

The most recent analyst rating on (OPTN) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Optinose stock, see the OPTN Stock Forecast page.

Spark’s Take on OPTN Stock

According to Spark, TipRanks’ AI Analyst, OPTN is a Neutral.

Optinose’s overall stock score is low, primarily due to significant financial challenges such as persistent losses, high leverage, and negative equity. While there are positive technical indicators, caution is warranted due to potential overbought conditions. The valuation metrics further underscore the risk, with a negative P/E ratio indicating continued unprofitability. A strategic turnaround is essential for improving the company’s financial health and stock performance.

To see Spark’s full report on OPTN stock, click here.

More about Optinose

Average Trading Volume: 94,069

Technical Sentiment Signal: Sell

Current Market Cap: $95.4M

For detailed information about OPTN stock, go to TipRanks’ Stock Analysis page.